Detalles de la búsqueda
1.
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
J Surg Oncol
; 120(4): 786-793, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368160
2.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Int J Gynecol Cancer
; 29(6): 1050-1056, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31263024
3.
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Lancet Oncol
; 19(12): 1680-1687, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413383
4.
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
Int J Gynecol Cancer
; 28(4): 729-737, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498983
5.
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Int J Gynecol Cancer
; 27(1): 50-58, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27749456
6.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med
; 363(10): 943-53, 2010 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20818904
7.
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Lancet Oncol
; 12(3): 236-44, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21354370
8.
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Oncology
; 79(1-2): 98-104, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21079407
9.
Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
Int J Gynecol Cancer
; 20(1): 164-72, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20057287
10.
Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
Oncology
; 76(2): 133-41, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19174612
11.
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Ecancermedicalscience
; 13: 891, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792808
12.
Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer.
Breast J
; 15(5): 551-3, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19671111
13.
Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
J Cancer Res Ther
; 10(4): 967-72, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25579538
14.
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
PLoS One
; 9(10): e109611, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25330188
15.
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Clin Transl Oncol
; 11(8): 554-7, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19661033
Resultados
1 -
15
de 15
1
Próxima >
>>